No new safety signals were reported with the androgen receptor pathway inhibitor.
Danielle Ternyila
Advertisement
Articles by Danielle Ternyila
Advertisement
Latest Updated Articles
Subgroup data sustain enzalutamide PFS benefit in nmCRPCPublished: December 7th 2020 | Updated:
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
3
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
4
Interpreting PSMA PET Imaging in Prostate Cancer
5